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The DNA mismatch repair (MMR) pathway recognizes and repairs
errors in base pairing and acts to maintain genome stability. Cancers
that have lost MMR function are common and comprise an
important clinical subtype that is resistant to many standard of care
chemotherapeutics such as cisplatin. We have identified a family of
rhodium metalloinsertors that bind DNA mismatches with high
specificity and are preferentially cytotoxic to MMR-deficient cells.
Here, we characterize the cellular mechanism of action of the most
potent and selective complex in this family, [Rh(chrysi)(phen)(PPO)]2+
(Rh-PPO). We find that Rh-PPO binding induces a lesion that triggers
the DNA damage response (DDR). DDR activation results in cell-
cycle blockade and inhibition of DNA replication and transcription.
Significantly, the lesion induced by Rh-PPO is not repaired in MMR-
deficient cells, resulting in selective cytotoxicity. The Rh-PPO mecha-
nism is reminiscent of DNA repair enzymes that displace mismatched
bases, and is differentiated from other DNA-targeted chemothera-
peutics such as cisplatin by its potency, cellular mechanism, and se-
lectivity for MMR-deficient cells.
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DNA mismatch repair (MMR) corrects mismatched basepairs that arise from replication errors and is involved in the
recognition and processing of DNA damage induced by chemo-
therapeutics such as cis-diamminedichloroplatinum(II) (cisplatin)
(1, 2). Loss of function of the MMR pathway is an important
mechanism for mutation generation and predisposition to cancer.
Lynch syndrome, an inherited condition characterized by suscep-
tibility to develop colon cancer, results from germline inactivation
of the MMR pathway (3). Somatic loss of function of the MMR
pathway occurs in 10–25% of cancers of the colon, endometrium,
ovary, and other tissue types (3–5). MMR-deficient cancer cells
display a 100- to 1,000-fold increase in mutation rate and are re-
sistant to many DNA-targeted chemotherapeutics (6, 7). Because
of this, patients with MMR-deficient cancers do not benefit from
standard of care therapy including cisplatin (8, 9). New therapies
that target these patient populations are needed.
We have previously described a class of octahedral rhodium(III)
complexes, termed metalloinsertors, as a strategy toward the tar-
geted therapy of MMR-deficient cancers. These compounds contain
a sterically expansive 5,6-chrysenequinone diimine ligand (chrysi;
Fig. 1A) that binds with high specificity to DNA mismatches, in-
dependent of sequence context (10). X-ray crystal structures dem-
onstrate that the chrysi ligand is capable of inserting at the mismatch
from the DNA minor groove; this binding mode, called metal-
loinsertion, maintains duplex stacking but displaces the mismatched
bases into the major or minor groove (11, 12). As a consequence,
metalloinsertor binding preferentially inhibits DNA synthesis and
growth of cell lines that are MMR-deficient (13–15). Structure–
activity relationship studies reveal that compound selectivity and cell
potency are influenced by binding affinity, rate of compound diffu-
sion into cells, and levels of compound accumulation in the cell
nucleus relative to the mitochondria (14–16). These studies support
the idea that cytotoxicity of the metalloinsertors results from tar-
geting mismatches in the nuclear DNA.
One of the first-generation compounds, [Rh(HDPA)2chrysi]
3+
(Rh-HDPA; HDPA= 2,2′dipyridylamine), was shown to increase the
percentage of cells in G2/M phase, leading to cell death by necrosis
(15). However, the poor cell potency of Rh-HDPA (EC50 = 25 μM),
coupled with just a twofold selectivity for MMR-deficient cells, lim-
ited cellular mechanism of action studies. Recently, newer-generation
compounds with up to 100-fold improved cell potency over Rh-
HDPA have been identified (17). The most potent compound,
[Rh(chrysi)(phen)(PPO)]2+ [Rh-PPO; phen = 1,10-phenanthroline;
PPO = 2-(pyridine-2-yl)propan-2-ol] (Fig. 1A), also has increased
selectivity for MMR-deficient cells (17). The mechanism behind the
increased cell potency and selectivity of Rh-PPO is not understood,
as its binding affinity, specificity for mismatches, and cellular uptake
characteristics are comparable to those of Rh-HDPA.
Rh-PPO and other newer-generation metalloinsertors contain
an unusual ligand coordination. Where early iterations of com-
plexes comprised an all-nitrogen coordination environment, the
next-generation metalloinsertors contain an axial Rh–O bond (Fig.
1A). This ligand coordination reduces the overall charge of the
complex from [3+] to [2+], consequently raising the pKa of the chrysi
imminium proton above biological pH. X-ray crystallographic
analysis of these structures reveals that the fully protonated chrysi
ligand adopts a buckled rather than planar conformation, which it
retains when bound to DNA (17). This binding mode may con-
tribute to the potent cellular activity of the compounds.
Significance
We have developed a family of rhodium compounds that bind
DNA mismatches and are cytotoxic to mismatch repair (MMR)-
deficient cancer cells. This study describes the cellular mecha-
nism of action of the compounds that enables this selective
cytotoxicity. The compound binding mode, metalloinsertion,
displaces the mismatched base pairs from the DNA helix and
creates a DNA lesion that activates the DNA damage response.
This lesion is unable to be repaired in MMR-deficient cells. This
mechanism is distinct from other compounds that target DNA
and provides a therapeutic strategy for treatment of cancers
with MMR deficiency.
Author contributions: J.M.B., A.G.W., and J.K.B. designed research; J.M.B., A.G.W., and
N.F.M. performed research; J.M.B., A.G.W., N.F.M., and J.K.B. analyzed data; and J.M.B.,
A.G.W., and J.K.B. wrote the paper.
Reviewers: D.L.B., The Scripps Research Institute; and D.W., University of California,
San Diego.
The authors declare no conflict of interest.
1To whom correspondence may be addressed. Email: jbailis@amgen.com or jkbarton@
caltech.edu.
2Present address: Publication Division, American Chemical Society, Washington, DC 20036.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1706665114/-/DCSupplemental.
6948–6953 | PNAS | July 3, 2017 | vol. 114 | no. 27 www.pnas.org/cgi/doi/10.1073/pnas.1706665114
Here, we use Rh-PPO as a tool compound to investigate the
cellular mechanism of action of the current generation of met-
alloinsertors. We find that Rh-PPO inhibits DNA transcription, in
addition to DNA synthesis, and blocks cell-cycle progression. Rh-
PPO activity induces DNA damage and activates the DNA damage
response (DDR). DDR activation leads to cell death by a non-
apoptotic mechanism, unlike other DNA-targeted chemotherapeu-
tics such as cisplatin that induce apoptosis following DDR activation.
We propose that Rh-PPO binding, and the resulting displacement of
mismatched base pairs from the helix, creates a lesion that is rec-
ognized by the DDR pathway. This activity is reminiscent of cer-
tain DNA repair enzymes that flip out damaged base pairs upon
binding (18). However, in the case of Rh-PPO, DDR activation is
not followed by repair in MMR-deficient cells, and we propose
that Rh-PPO binding blocks processing of the mismatched base
pairs by repair enzymes. As the mechanism by which metalloinsertors
initiate their selective cytotoxic effects becomes increasingly clear,
next-generation complexes with enhanced potency and selectivity
represent a potential translational avenue for targeting MMR-
deficient cancers.
Results
Rh-PPO Is Selectively Cytotoxic to MMR-Deficient Cells. Rh-PPO
(Fig. 1A) was identified in structure–activity relationship studies of
metalloinsertors with an axial Rh–O bond and was found to have
nearly 100-fold increased cell potency relative to earlier-generation
compounds (17). To further characterize the cytotoxic activity of
Rh-PPO, we carried out a dose–response assay in the matched
colorectal cancer cell lines HCT-116 N (MMR-proficient) and HCT-
116 O (MMR-deficient) (19). After 72 h incubation, viable cells were
counted using high-content imaging. Rh-PPO decreased cell viability
in the MMR-deficient HCT-116 O cells with an EC50 of 0.15 ±
0.06 μM (Fig. 1B). The number of MMR-proficient HCT-116 N
cells was affected only at 10-fold higher compound concentrations
(EC50 = 1.12 ± 0.27 μM) (Fig. 1B). In time-lapse imaging studies,
0.5 μM Rh-PPO, a concentration above the cell EC90, blocked cell
division of HCT-116 O cells within the first 24 h and induced cell
swelling and bursting at later time points, consistent with cell death
(Fig. 1C). In contrast, the same concentration of Rh-PPO in HCT-
116 N cells did not impact cell growth, and cells retained a normal
morphology (Fig. 1C). The growth rate of Rh-PPO–treated HCT-
116 N cells was similar to that of untreated cells (Fig. S1).
The selective cytotoxicity of Rh-PPO for HCT-116 O cells ex-
tended to otherMMR-deficient cancer cell lines. In an NCI-H23 lung
cancer cell line engineered with an inducible shRNA to MLH1 (20),
we found that Rh-PPO inhibited viability of cells that had down-
regulated MLH1 with an EC50 of 0.39 ± 0.07 μM, whereas the
MLH1-expressing cells had an EC50 of 2.6 ± 0.33 μM (Fig. S2). In a
panel of nonmatched ovarian cancer cell lines, Rh-PPO also prefer-
entially induced cytotoxicity of MMR-deficient cells (average EC50 of
0.07 μM; range 0.06–0.10 μM) compared with MMR-proficient cells
(average EC50 of 0.23 μM; range 0.10–0.26 μM) (Fig. S3). These
findings demonstrate that Rh-PPO has broad activity against MMR-
deficient cells and suggest that the phenotype of MMR deficiency,
rather than loss of function of a specific MMR protein such as
MLH1 or MSH2, is critical for the metalloinsertor selectivity.
The selectivity of Rh-PPO for MMR-deficient cells is opposite
to that of cisplatin, a DNA-targeted chemotherapeutic which
creates intrastrand cross-links and adducts that are preferentially
cytotoxic toward MMR-proficient cells. Cisplatin decreased cell
viability in HCT-116 O cells with an EC50 of 3.98 ± 0.21 μM, and
in HCT-116 N cells with an EC50 of 1.45 ± 0.09 μM, after a 72-h
incubation (Fig. 1B). In time-lapse imaging studies, cells treated
with 5 μM cisplatin, a concentration over the cell EC90, initially
continued to grow and divide and exhibited an increased cell size
before undergoing cell death (Fig. 1C). Rh-PPO is both more
potent and more selective than cisplatin for MMR-deficient cells,
and appears to act by a different mechanism than cisplatin.
Rh-PPO Inhibits Transcription. Metalloinsertor binding to a DNA
mismatch might directly or indirectly block chromosomal processes
such as DNA replication, transcription, or DNA repair. As part of
the initial characterization of Rh-PPO, we found that incorporation
of bromodeoxyuridine, a marker for DNA synthesis, was inhibited
62% more in MMR-deficient HCT-116 O cells compared with
HCT-116 N cells (17). To test whether Rh-PPO also inhibits tran-
scription, we used high-content imaging to evaluate incorporation of
the modified nucleotide ethynyl uridine (EU) into newly synthe-
sized RNA. A 24-h treatment with Rh-PPO efficiently inhibited EU
uptake in the MMR-deficient HCT-116 O cells, with an EC50 of
0.09 ± 0.02 μM (Fig. 2A). EU uptake in HCT-116 N cells was
inhibited only at much higher concentrations of Rh-PPO (EC50 =
0.81 ± 0.18 μM; Fig. 2A). At 0.5 μMRh-PPO, a concentration over
the cell EC90, EU incorporation was inhibited in most HCT-116 O
cells, whereas EU uptake in HCT-116 N cells was similar to that in
cells that were not treated with compound (Fig. 2B). Comparable
results were obtained using an ELISA readout (Fig. S4). Rh-PPO
therefore selectively inhibits transcription in MMR-deficient cells.
Cisplatin inhibited transcription in both HCT-116 O and HCT-
116 N cells, with preferential effects on the MMR-proficient cells.
At a 5 μM concentration, EU incorporation was below the level of
detection in 23.8% of HCT-116 O cells and 39.4% of HCT-116 N
cells (Fig. 2 A and B).
A
C
B
Fig. 1. Rh-PPO arrests cell-cycle progression of MMR-deficient cells.
(A) Chemical structure of Rh-PPO. (B) HCT-116 O and HCT-116 N cells were
treated with Rh-PPO or cisplatin in a dose–response. Cell viability was eval-
uated at 72 h using a Cell Titer-glo assay. The graph displays percent viable
cells for duplicate samples treated with compound. (C) HCT-116 O and HCT-
116 N cells were treated with 0.5 μM Rh-PPO or 5 μM cisplatin and imaged by
DIC microscopy over 72 h; representative images from the time course are
shown. Cells are imaged at 20× magnification. (Scale bar, 100 μM.)
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Rh-PPO Activates the DDR. Metalloinsertor binding at a DNA
mismatch displaces the mismatched base pairs from the helix
stack into the major or minor groove (11, 12). Whereas this
binding mode may present a physical block to DNA unwinding, we
also considered whether the displaced base pairs may be recog-
nized as a lesion by cell surveillance checkpoints. We first evalu-
ated phosphorylated histone H2AX (pH2AX), an early marker for
activation of the DDR that correlates with the presence of DNA
double-strand breaks (DSBs) in the cell nucleus (21). Treatment
with Rh-PPO increased the percentage of pH2AX-positive cells at
24 h preferentially in HCT-116 O cells (Fig. 3A). In the presence
of 0.5 μMRh-PPO, 50.8 ± 1.2% of HCT-116 O cells were positive
for pH2AX, and just 11.5 ± 0.7% of HCT-116 N cells were pos-
itive for pH2AX (Fig. 3 A and B). As a comparison, we examined
pH2AX induction in cells treated with cisplatin, which generates
DSBs as a consequence of the processing of intrastrand cross-
links. The cisplatin-treated cells displayed high levels of pH2AX
staining at 24 h, notably with opposite selectivity to Rh-PPO (Fig.
3A). With 5 μM cisplatin treatment, 38.2 ± 5.4% HCT-116 O cells,
compared with 69.6 ± 1.7% HCT-116 N cells, were pH2AX-
positive (Fig. 3 A and B). Untreated HCT-116 O and HCT-116
N cells contained a low percentage of pH2AX-positive cells (Fig.
3B), consistent with occasional, spontaneous DNA damage that
occurs during DNA replication (22).
The initial damage signal induced by Rh-PPO was amplified by
phosphorylation of the checkpoint protein kinase Chk1, a trans-
ducer of the DDR signal that is associated with regions of single-
stranded DNA (23). After 24 h treatment with 0.5 μM Rh-PPO,
59.2 ± 0.9% of HCT-116 O cells contained nuclear, phosphorylated
Chk1 (pChk1), and 20 ± 1.3% of HCT-116 N cells displayed pChk1
(Fig. S5). Cisplatin also increased Chk1 phosphorylation, with
46.9 ± 11.9% of HCT-116 O cells and 72.3 ± 1.7% of HCT-116 N
cells exhibiting pChk1 staining after 24 h treatment with 5 μM
cisplatin (Fig. S5). Together, these data suggest that Rh-PPO
binding generates an aberrant structure that is recognized as a le-
sion by the DDR. The striking difference in selectivity of Rh-PPO
compared with cisplatin suggests that requirements for processing
of their respective lesions are completely distinct.
The Rh-PPO Lesion Generates DNA Damage but Does Not Activate
Apoptosis. Normally, activation of the DDR would trigger repair
of a DNA lesion or lead to apoptosis if the DNA damage is severe.
To understand more about the nature of the lesion generated by
Rh-PPO, we first examined cellular levels of reactive oxygen spe-
cies (ROS), which are a potential source of DNA DSBs. At 0.5 μM
Rh-PPO, a concentration above the cell EC90 that was sufficient to
induce DDR activation and cell death, ROS levels were only in-
creased slightly, to levels 1.5× that of untreated cells after 72 h (Fig.
4A). We used a Comet assay to assess damage to nuclear DNA
such as DSBs and single-strand breaks. After 24 h treatment with
0.5 μM of Rh-PPO, 64.0 ± 4.0% of HCT-116 O nuclei displayed
Comet tails indicating the presence of fragmented DNA, whereas
just 27.0 ± 7.0% of HCT-116 N nuclei generated Comet tails (Fig.
4B). Background levels of DNA damage in untreated HCT-116 O
and HCT-116 N cells were 18.4 ± 4.0%. The damage caused by
Rh-PPO may be distinct from that generated by cisplatin, which
caused an increase in both ROS levels and fragmented DNA, with
a stronger effect observed in the MMR-proficient HCT-116 N
cells: 51.0 ± 1.5% of HCT-116 N nuclei displayed Comet tails
versus 32.0 ± 10.0% of HCT-116 O nuclei (Fig. 4B).
The lesion generated by Rh-PPO occurred within the first cell
cycle. Rh-PPO blocked cell-cycle progression of HCT-116 O cells
within 24 h (Fig. 1C). This is consistent with our initial observation
that metalloinsertor treatment led to an accumulation of cells in
the G2/M phase (17). Interestingly, the cell death triggered by Rh-
PPO occurred primarily by a nonapoptotic pathway, and the ac-
tivity of caspases 3 and 7 was not increased (Fig. 4C). In addition,
cells treated with 0.5 μM Rh-PPO did not exhibit nuclear frag-
mentation characteristic of apoptotic cells (Fig. 4D).
The cell morphology resulting from Rh-PPO treatment is
distinct from that of cisplatin. Cells treated with cisplatin did not
A
B
Fig. 2. Rh-PPO inhibits transcription. (A) HCT-116 O and HCT-116 N cells
were treated with Rh-PPO or cisplatin in a dose–response for 24 h. EU in-
corporation into cells was evaluated using a Click-It assay followed by high
content imaging. The percent EU-positive cells from duplicate samples are
shown. (B) Representative images of HCT-116 O and N cells treated with
0.5 μM Rh-PPO or 5 μM cisplatin (from A) stained for EU (pink) and DAPI
(blue) to mark the cell nucleus are shown. Cells were imaged at 20× mag-
nification. (Scale bar, 100 μM.)
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appear to arrest in the first cell cycle, but rather continued to
grow and divide, generating fragmented nuclei by 72 h (Fig. 4D).
Consistent with this observation, 5 μM cisplatin efficiently induced
caspase activation (Fig. 4C). Together, these data support a model
in which Rh-PPO generates a lesion that is processed in a com-
pletely different way than cisplatin and thus enables selective cy-
totoxicity against MMR-deficient cells (Fig. 5).
Discussion
In this study we describe the mechanism of action of Rh-PPO, a
new-generation metalloinsertor with high cell potency and se-
lectivity for MMR-deficient cancer cells. Rh-PPO inserts from
the DNA minor groove at thermodynamically destabilized mis-
match sites, and the resulting displacement of the mismatched
bases from the helical stack generates a lesion that activates the
DDR and leads irreversibly to nonapoptotic cell death. We
propose that the selectivity of Rh-PPO is driven by its binding to
DNA mismatches in the cell nucleus, which occur at up to 1,000-
fold higher levels in MMR-deficient cells relative to MMR-
proficient cells (6, 7). We propose that the high cell potency of
Rh-PPO derives from the buckled orientation of the chrysi li-
gand in the DNA minor groove, which gives distinct positioning
and potentially increased extrusion of the mismatched base pairs
compared with earlier generation metalloinsertors; other char-
acteristics of the metal complexes, including binding affinity and
cellular uptake, are similar (17).
The lesion generated by Rh-PPO binding is clearly different from
that generated by cisplatin. Cisplatin binding to DNA primarily
forms intrastrand cross-links, such as 1,2- intrastrand d(GpG) ad-
ducts, that are converted to DSBs as cells progress through S phase,
leading to activation of the DNA damage response and apoptosis
(24–26). Cisplatin preferentially targets MMR-proficient cells, in
part due to the role of MMR proteins in recognition and processing
of the lesions (1, 2). Insight into the differences between metal-
loinsertors and platinum complexes can also be drawn from analysis
of bimetallic rhodium–platinum complexes (27, 28). A conjugate
of cisplatin to one of the newer-generation metalloinsertors,
[Rh(chrysi)(phen)(DPE)]2+ [DPE = 1,1-di(pyridine-2-yl)ethanol],
bound DNA both noncovalently through metalloinsertion at a
mismatch and covalently through platinum binding at N3-adenine
in the minor groove (28). This bimetallic complex preferentially
targeted mismatched DNA and showed improved cell potency
relative to cisplatin, but the complex lost specificity for MMR-
deficient cancer cells and induced cell death primarily by apopto-
sis, not unlike cisplatin (28). This result suggests that the covalent
linkage of cisplatin to DNA dominates the cellular response to the
bimetallic complexes.
Rh-PPO is also distinct from other compounds that are reported
to preferentially target MMR-deficient cells. Cytosine-based nu-
cleoside analogs such as cytarabine generate high levels of ROS and
are proposed to preferentially induce apoptosis in MMR-deficient
cells by destabilizing the membrane potential of mitochondria (29).
Triamterene, a diuretic drug, increases ROS and induces apoptosis
through a mechanism that requires thymidine synthase activity (30).
Coincubation with folates abolishes the cytotoxic activity of tri-
amterene against MMR-deficient cells (30), suggesting that in vivo,
cancer cells may be able to develop resistance to this drug.
The Rh-PPO mechanism is reminiscent of lesion-specific DNA
glycosylases that probe destabilized regions of the genome and,
upon binding, flip the mismatched base into the enzyme active site
(31, 32). Indeed, the first-generation metalloinsertor, similar to a
glycosylase, was able to photochemically cleave DNA at a mis-
match site (31, 33). A mismatch bound by a glycosylase typically
would undergo further processing such as base excision and repair
(18). However, in the case of Rh-PPO, we propose that metal-
loinsertor binding blocks access of DNA repair enzymes to the
lesion. A mismatch-specific glycosylase might not be able to rec-
ognize mismatched bases that have already been ejected from the
stacked helix. Alternatively, it is possible that the lesion generated
by metalloinsertor binding requires MMR proteins for repair. The
cell death that follows Rh-PPO binding is unusual in that it is
A
B
Fig. 3. Rh-PPO increases phosphorylation of histone H2AX. HCT-116 O and
HCT-116 N cells were treated with Rh-PPO or cisplatin in a dose–response for
24 h, and then stained for pH2AX, a marker for DNA DSBs, by indirect im-
munofluorescence. (A) Percent positive cells from duplicate samples are
graphed. (B) Representative images of pH2AX staining (pink) are shown
(from A); nuclear DNA is stained with DAPI (blue). All images are at 20×
magnification. (Scale bar, 100 μM.)
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primarily nonapoptotic. It may be that the unusual nature of the
Rh-PPO lesion fails to be recognized by the apoptotic machinery.
Alternatively, cells may default to necrosis because signaling by
the DDR is unproductive; a similar mechanism was proposed for
taxanes, which trigger prolonged signaling of the spindle micro-
tubule assembly checkpoint leading eventually to nonapoptotic
cell death (34). Our current efforts are focused on defining a high-
resolution crystal structure of the Rh-PPO/DNA complex and
exploring the kinetics of association of DNA repair proteins with
the displaced bases.
Until recently, therapeutic options for treatment of MMR-deficient
cancers have been limited. Chemotherapy has been the standard of
care despite lack of evidence for benefit with this treatment (8, 9).
Prospective testing for MMR deficiency has mainly been limited to
colorectal cancer (35). The mechanism of action that we demon-
strate for Rh-PPO offers the possibility of therapeutic strategies
targeted specifically to cancers associated with deficiencies in MMR.
Materials and Methods
Compounds. Rh-PPO was synthesized as described previously (17). Compound
concentration was calculated by UV/Vis spectroscopy based on the previously
reported extinction coefficient (17). Cisplatin was obtained from Sigma. Rh-
PPO and cisplatin were dissolved in Milli-Q water and stored at room tem-
perature in the dark.
Cell Lines and Culture. HCT-116 O and HCT-116 N cells are HCT-116 colorectal
cancer cells that have been modified to contain Chromosome 2 (O; MMR-
deficient) or Chromosome 3 that bears wild-type MLH1 (N; MMR-proficient)
(19). HCT-116 O and HCT-116 N cells were also engineered to stably express
histone H2B-green fluorescent protein (H2B-GFP). Histone H2B-GFP from the
pBOS-H2B-GFP vector (Becton Dickinson) was subcloned into the SalI/ NotI re-
striction sites of the pENTR vector (Life Technologies), and then moved into the
Gateway-compatible lentiviral vector pLV418G (36). The construct was packaged
into lentivirus which was used to transduce cells. Cells that had stably integrated
histone H2B-GFP into the chromosome were selected with zeocin and expanded.
Cells were grown and maintained in Roswell Park Memorial Institute
(RPMI) media that contained 10% FBS, 1% penicillin/streptomycin, 1× non-
essential amino acids, 1 mM sodium pyruvate, and 1 mM L-glutamine, to
which 400 μg/mL geneticin (Gibco) was added. Cells were maintained at
37 °C with 5% CO2.
Cell Assays. Cells were plated to 96-well View Plates (Perkin-Elmer) and
allowed to adhere overnight. Cells were then treated with compounds in a
dose–response for 24–72 h. The treated cells were assayed directly, as de-
scribed below, or were fixed in 4% formaldehyde and permeabilized with
0.5% Triton X-100 in PBS before antibody staining for indirect immunoflu-
orescence. Cells were blocked in 1× blocking buffer (Thermo Fisher), and
incubated with primary antibody at 1:100 overnight at 4 °C. Cells were then
washed in PBS and incubated with secondary antibody and 4′,6-diamidino-2-
phenylindole (DAPI; Sigma) at 1:1,000. High-content imaging (Cellomics
ArrayScan, Thermo Fisher) was used to collect and analyze images as well as
for cell viability based on nuclear count.
Extrusion of 
Mismatched Bases
DNA Damage 
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Non-Apoptotic    
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Fig. 5. Model for activation of the DDR by Rh-PPO. Rh-PPO inserts in the
DNA minor groove at thermodynamically destabilized sites such as mis-
matched base pairs. The binding of Rh-PPO causes the mismatched bases to
flip to the outside of the DNA helix. The displaced bases generate a lesion
that activates the DDR. In MMR-deficient cells, the inability to repair the
lesion results in cell death primarily by a nonapoptotic mechanism.
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Fig. 4. Rh-PPO induces a nonapoptotic cell death. (A) HCT-116 O and HCT-116
N cells were treated with 0.5 μM Rh-PPO or 5 μM cisplatin, and ROS levels were
measured at the times indicated. (B) HCT-116 O and HCT-116 N cells treated
with 0.5 μM PPO or 5 μM cisplatin for 24 h were assayed for DNA damage
using the Comet assay. (Scale bar, 100 μM.) (C) Cells treated with Rh-PPO or
cisplatin in a dose–response were assayed for increased levels of caspases 3 and
7 at 24 h, using a Caspase Glo assay. RLU, relative light unit. (D) HCT-116 O cells
stably expressing histone H2B-GFP were treated with 0.5 μM Rh-PPO or 5 μM
cisplatin and then imaged at the times indicated. (Scale bar, 100 μM.)
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DNA transcription was evaluated with Click-It assays for 5-EU uptake,
performed according to the manufacturer’s protocol (Thermo Fisher). Cells
were pulse labeled with EU for 1 h before processing for antibody staining.
Activation of the DDR was evaluated by indirect immunofluorescence, using
primary antibodies against pH2AX and pChk1 (Cell Signaling). Secondary
antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 594 were from
Thermo Fisher. Cell nuclei were stained with DAPI. Cell viability was inde-
pendently assessed using Cell Titer-glo assays (Promega).
For live cell imaging studies, cells were plated to 35-mm dishes (MatTek)
that were precoated with rat collagen (Becton Dickinson). Just before im-
aging, fresh media and compound were added to the cells. Differential in-
terference contrast (DIC) and GFP images were collected every 4 h using a 540L
Zeiss confocal microscope; data were analyzed with Zen software (Zeiss).
Cellular ROS levels were assessed with a 2′,7′–dichlorofluorescein diacetate
(DCFDA)-reactive oxygen species detection assay (Abcam). Cells were plated
to Perkin-Elmer View plates, and then were treated with DCFDA for 1 h
before Rh-PPO or cisplatin were added in a dose–response for a total of 24 h.
The fluorescent compound 2′, 7′–dichlorofluorescein (DCF), a product of
DCFDA oxidation, was measured using a Tecan Safire2 microplate reader.
DNA damage was evaluated using a Comet assay (Cell Biolabs). Cells were
treated with compound as indicated, and then collected using a cell scraper,
mixed with melted agarose, and pipetted onto slides. The samples were
denatured and then analyzed by Tris/borate/EDTA gel electrophoresis at 35 V
for 20 min to separate DNA fragments from intact DNA. The samples were
then stained with a fluorescent dye to visualize the cellular DNA, and im-
aged using an EVOS cell-imaging system (Thermo Fisher).
Cell apoptosis was evaluated using a Caspase 3/7 Glo assay kit (Promega).
Cells treated with Rh-PPO or cisplatin in a dose–response for 24 h were in-
cubated with a substrate that luminesces upon cleavage by caspases. Lumi-
nescence was measured using an Envision plate reader (Perkin-Elmer).
All cellular assays were performed at least three times with duplicate
samples. Data were analyzed in Graph Pad (Prism). Statistical analysis was
carried out using the two-tailed Student’s t test, using mean and SE values
from three or more independent experiments. For the high content imaging
studies, 9 fields per well were collected at 20× magnification (>1,000 cells
per sample, with duplicate samples).
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